[Immunoprophylaxis of poliomyelitis in Ukraine with the use of inactivated vaccine].
In connection with the cessation of the circulation of "wild" poliovirus on the territory of the European region, including Ukraine, the strategy of the vaccinal prophylaxis of poliomyelitis is reviewed. Its main aims are the creation of a high level of the specific protection of the population, the prophylaxis of vaccine-associated paralytic poliomyelitis and a decrease in the intensity of the circulation vaccine polioviruses. These aims may be achieved only by the inclusion of vaccinations with inactivated poliomyelitis vaccine (IPV) into the immunization schedule. IPV "Imovax Polio" produced by the firm "Aventis Pasteur" (France) has been shown to have low reactogenicity and high effectiveness, especially with respect to type 3 poliovirus, under the conditions of Ukraine. On the basis of our studies all children, starting from the age of 3 months, are recommended to be vaccinated first with two injections of IPV, followed by further immunization with oral vaccine.
Frolov
A F
AF
Sel'nikova
O P
OP
Zadorozhnaia
V I
VI
Moiseeva
A V
AV
Demchishina
I V
IV
Bondarenko
V I
VI
Zubkova
N L
NL
Doan
S I
SI
Buraia
T A
TA
D000914:Antibodies, Viral / Q000097:blood; D045744:Cell Line, Tumor; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D009500:Neutralization Tests; D011051:Poliomyelitis / Q000097:blood / Q000276:immunology / Q000517:prevention & control*; D017955:Poliovirus / Q000276:immunology; D011054:Poliovirus Vaccine, Inactivated / Q000008:administration & dosage* / Q000276:immunology; D011055:Poliovirus Vaccine, Oral / Q000008:administration & dosage* / Q000276:immunology; D014455:Ukraine; D014611:Vaccination
D000914:Antibodies, Viral; D011054:Poliovirus Vaccine, Inactivated; D011055:Poliovirus Vaccine, Oral